Indication
Castration-resistant prostate cancer
Castration-resistant prostate cancer is an advanced, biologically aggressive malignancy of the male genitourinary system characterized by disease progression despite medical or surgical castration. Read more about Castration-resistant prostate cancer
1 drugs 1 manufacturers
Drugs that treat it
Common Castration-resistant prostate cancer therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCastration-resistant prostate cancer is an advanced, biologically aggressive malignancy of the male genitourinary system characterized by disease progression despite medical or surgical castration.
Pathophysiologically, the tumor circumvents systemic androgen deprivation through mechanisms such as androgen receptor amplification, mutations, or alternative signaling cascades that sustain tumor cell proliferation in an androgen-depleted environment.
It is clinically defined by objective radiographic progression or serial increases in serum prostate-specific antigen levels occurring in the presence of castrate serum testosterone levels below 50 ng/dL.
The condition encompasses both non-metastatic and metastatic stages, commonly spreading to regional lymph nodes, visceral organs, and bone.
- nih.gov
Castration-resistant prostate cancer is an advanced, biologically aggressive malignancy of the male genitourinary system characterized by disease progression despite medical or surgical castration Pathophysiologically, the tumor circumvents systemic androgen deprivation through mechanisms such as androgen receptor amplification, mutations, or alternative signaling cascades that sustain tumor cell proliferation in an androgen-depleted environment It is clinically defined by objective radiographic...
- mayoclinic.org
Castration-resistant prostate cancer is an advanced, biologically aggressive malignancy of the male genitourinary system characterized by disease progression despite medical or surgical castration The condition encompasses both non-metastatic and metastatic stages, commonly spreading to regional lymph nodes, visceral organs, and bone
- webmd.com
Pathophysiologically, the tumor circumvents systemic androgen deprivation through mechanisms such as androgen receptor amplification, mutations, or alternative signaling cascades that sustain tumor cell proliferation in an androgen-depleted environment
- cancer.ca
It is clinically defined by objective radiographic progression or serial increases in serum prostate-specific antigen levels occurring in the presence of castrate serum testosterone levels below 50 ng/dL The condition encompasses both non-metastatic and metastatic stages, commonly spreading to regional lymph nodes, visceral organs, and bone
Personalize your experience
Follow Castration-resistant prostate cancer and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.